A Phase 1a/1b, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YL201 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumors

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today